Advertisement

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

First International Summit on Interventional Pharmacoeconomics

Advertisement


Related Videos

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Advertisement

Advertisement



Jan
26
Today In Oncology
New Study Finds Suspicious Lesions on Breast MRI in Neoadjuvant Setting Are Unlikely to Be Malignant
IMpower133 Update Atezolizumab Plus Carboplatin/Etoposide for Extensive-Stage Small Cell Lung Cancer
Multiancestry Meta-analysis of Prostate Cancer Genetics
Final Overall Survival Results of the IDEA Collaboration 3 vs 6 Months of Adjuvant Chemotherapy for Stage III Colon Cancer
Integrated Palliative and Oncology Care for Patients Receiving Treatment for Acute Myeloid Leukemia
View More 
Advertisement
© 2021 HSP News Service, L.L.C.
Designed by Harborside